Healthcare Industry News: Cook
News Release - September 7, 2006
IntraOp Medical Announces Two Key Promotions to Management TeamCompany Strengthens Infrastructure to Support Growing Demand for Its Revolutionary Mobetron(R) Device
SUNNYVALE, Calif.--(HSMN NewsFeed)--Sept. 7, 2006--IntraOp Medical Corporation (OTCBB: IOPM ) has promoted Rick Belford to Vice President of Quality Assurance and Regulatory Affairs, and Tom Cook to Director of Customer Support. These two newly created positions strengthen IntraOp's corporate infrastructure, while adding support for the growing demand of the Company's Mobetron system, an FDA-cleared device used to deliver intraoperative electron radiation therapy (IOERT) during cancer surgery.
Mr. Belford has over 30 years of quality assurance and regulatory affairs experience within the medical technology industry. For the past eight years, Mr. Belford has served as IntraOp's Director of Quality Assurance and Regulatory Affairs. In his new capacity as Vice President of Quality Assurance and Regulatory Affairs, he will have increased responsibility for overseeing all aspects of the Company's quality programs and worldwide regulatory compliance. IntraOp Medical is certified to the ISO 13485:2003 standard for medical device manufacturing and maintains 510(k) FDA approval for the Mobetron in the U.S., CE mark in Europe, JIS in Japan, and SDA in China.
In addition, Tom Cook, who has over 30 years of radiation therapy device service and management experience, has been named Director of Customer Support. Mr. Cook has served as IntraOp's Service Manager since 1995. As Director, he will oversee the installation of new Mobetron systems, the training of technicians who operate the Mobetron in hospitals, and the growing IntraOp service business provided by IntraOp's own personnel and its distributor's worldwide.
"The promotions of Mr. Belford and Mr. Cook strengthen two very critical components of our business: maintaining worldwide regulatory compliance of the Mobetron and providing superior customer service and support," said Dr. Donald A. Goer, Chairman and Chief Executive Officer of IntraOp Medical. "These promotions will add depth and flexibility to our management team while enabling us to effectively support the growing demand for the Mobetron worldwide."
In related company news, IntraOp announced that Mr. Paul J. Crowe, who is also the founder, Chairman and CEO of Nuview Radiopharmaceuticals Corporation, has resigned from the Company's board of directors due to his other business commitments.
"Paul has been a great asset to IntraOp," commented Dr. Goer. "He helped give the company guidance and direction during his tenure, and his presence will be missed."
About IntraOp Medical Corporation
IntraOp Medical Corporation improves the quality of life for cancer patients through the development, manufacturing and sales of its proprietary Mobetron system. The Mobetron is a mobile electron-beam accelerator designed exclusively for intraoperative electron radiation therapy (IOERT), the direct application of radiation to a tumor while a patient is undergoing cancer surgery. The system makes IOERT widely available, cost effective, and simple to deliver because it is easily transportable between operating rooms and does not require a cost-prohibitive, radiation shielded surgical suite. The system is FDA-certified for sale in the United States and has received the equivalent foreign approvals: CE Mark in Europe, JIS in Japan and SDA in China. IntraOp Medical Corporation is based in Sunnyvale, California.
For more information please visit www.intraopmedical.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.